The emerging nanomedicine landscape

By Volker Wagner, Anwyn Dullaart, A. Bock, A. Zweck. Nature Biotechnology, 2006

1,557 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Clinical Translation of Nanomedicine (2015, neutral): “Primary end points were (1) noninferiority of PFS for PLD as compared to doxorubicin and (2) cardiotoxicity rates in the two arms.”
Interactions of nanomaterials and biological systems: implications to personalized nanomedicine (2012, background): “The other nanomedicine products include in vivo imaging agents, in vitro diagnostics, biomaterials, and active implants [18].”
Nanotechnological applications in medicine. (2007, methodology): “Within the past decade, there has been a plethora of new research, development and patent activities around nanoscaled technologies in the health sciences field [2 ].”
Nanoparticle PEGylation for imaging and therapy (2011, background): “Nanoparticles (NPs) are synthetic materials with dimensions from one to hundreds of nanometers, and remarkable applications in biomedicine due to the unique way in which they interact with matter [1,2].”
Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. (2008, background): “of efficiently encapsulating and delivering a variety of drug classes.(5,6) Polymeric NPs”